Department of Chemistry, Alice Campus, University of Fort Hare, Alice 5700, South Africa.
Int J Mol Sci. 2021 Jun 26;22(13):6869. doi: 10.3390/ijms22136869.
Metastatic bone cancer occurs in every type of cancer but is prevalent in lung, breast, and prostate cancers. These metastases can cause extensive morbidity, including a range of skeletal-related events, often painful and linked with substantial hospital resource usage. The treatment used is a combination of chemotherapy and surgery. However, anticancer drugs are still limited due to severe side effects, drug resistance, poor blood supply, and non-specific drug uptake, necessitating high toxic doses. Bisphosphonates are the main class of drugs utilized to inhibit metastatic bone cancer. It is also used for the treatment of osteoporosis and other bone diseases. However, bisphosphonate also suffers from serious side effects. Thus, there is a serious need to develop bisphosphonate conjugates with promising therapeutic outcomes for treating metastatic bone cancer and osteoporosis. This review article focuses on the biological outcomes of designed bisphosphonate-based conjugates for the treatment of metastatic bone cancer and osteoporosis.
转移性骨癌发生于每一种癌症，但在肺癌、乳腺癌和前列腺癌中更为常见。这些转移可导致广泛的发病率，包括一系列与骨骼相关的事件，通常是疼痛的，并与大量医院资源的使用有关。所使用的治疗方法是化疗和手术的结合。然而，由于严重的副作用、耐药性、血液供应不良和非特异性药物摄取，抗癌药物仍然有限，需要高毒性剂量。双膦酸盐是用于抑制转移性骨癌的主要药物类别。它也用于治疗骨质疏松症和其他骨疾病。然而，双膦酸盐也有严重的副作用。因此，迫切需要开发具有治疗转移性骨癌和骨质疏松症有前景的治疗效果的双膦酸盐缀合物。本文综述了设计的基于双膦酸盐的缀合物在治疗转移性骨癌和骨质疏松症中的生物学结果。
Zotero 插件
